Linagliptin Viatris

Linagliptin, the active ingredient in Linagliptin Viatris, is a Dipeptidyl peptidase-4 (DPP-4) inhibitor presented as an oral tablet for systemic use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycaemic control when used with diet and exercise.

GNH USA supplies Linagliptin Viatris as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams across global markets, ensuring regulatory‑approved quality and reliable delivery with comprehensive documentation and support for import requirements.

Linagliptin is a DPP-4 inhibitor used in the management of type 2 diabetes mellitus. - Type 2 diabetes mellitus: improves overall blood glucose control as part of a comprehensive treatment plan. - Monotherapy in adults: lowers HbA1c levels when used alone with diet and exercise. - Combination therapy: enhances glycaemic control when added to metformin, sulfonylureas or insulin.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nasal passages and throat. - Headache: transient mild to moderate head pain. - Dizziness: occasional sensation of light‑headedness. - Gastrointestinal upset: includes nausea, abdominal discomfort, or diarrhoea. - Back pain: occasional musculoskeletal discomfort. - Arthralgia: joint pain without swelling.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: including rash, angioedema, or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice. - Hypoglycaemia: especially when combined with insulin or sulfonylureas. - Bullous pemphigoid: rare autoimmune skin disorder.

Before initiating therapy, consider the following precautions: - Renal function: no dose adjustment required, but monitor renal status regularly. - Hepatic impairment: use with caution and assess liver function tests. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Cardiovascular disease: monitor for any adverse cardiac events. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Linagliptin may interact with several medicines; review patient medication lists carefully. Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase linagliptin exposure. - Rifampin or other potent enzyme inducers: can reduce therapeutic effect. - Co‑administration with insulin secretagogues: heightened risk of hypoglycaemia. Moderate Interactions (Monitor Closely):\n- Diuretics: may affect glucose homeostasis. - Antihypertensive agents: monitor blood pressure changes. - Anticoagulants: observe for any alteration in coagulation parameters.